Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms

International Journal of Tryptophan Research

Volumn 5, Issue 1, 2013, Pages 1-8

  Cruz, Verónica Pérez De La ^a   Carrillo Mora, Paul ^a   Santamaría, Abel ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Excitotoxicity; Neurodegeneration; Oxidative stress; Quinolinate; Toxic mechanisms

Indexed keywords

EID: 84877881003     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S8158     Document Type: Review

References (40)

1. Pérez-De La Cruz V, Königsberg M, Santamaría A. Kynurenine pathway and disease: an overview. CNS Neurol Disord Drug Targets. 2007;6:398-410.
2. Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol. 2010;90:230-45.
3. Backhaus C, Rahman H, Scheffler S, Laatsch H, Hardeland R. NO scavenging by 3-hydroxyanthranilic acid and 3-hydroxykynurenine: N-nitrosation leads via oxadiazoles to o-quinone diazides. Nitric Oxide. 2008;19:237-44.
4. Chen Y, Meininger V, Guillemin GJ. Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors. Cent Nerv Syst Agents Med Chem. 2009;9:32-9.
5. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002;303:1-10.
6. Chiarugi A, Sbarba D, Paccagnini A, Donnini S, Filippi S, Moroni F. Combined inhibition of indoleamine 2,3-dioxygenase and nitric oxide synthase modulates neurotoxin release by interferon-gamma-activated macrophages. J Leukoc Biol. 2000;68:260-6.
7. McLin JP, Thompson LM, Steward O. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur J Neurosci. 2006;24:3134-40.
8. Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. TiBS. 2010;35: 505-13.
9. Platenik J, Stopka P, Vejrazka M. Quinolinic acid-iron (II) complexes: slow autooxidation, but enhanced hydroxyl radical production in the Fenton reaction. Free Radic Res. 2001;34:445-59.
10. Pellegrini-Giampietro DE, Cherici G, Alesiani M, Carla V, Moroni F. Excitatory amino acid release from rat hippocampal slices as a consequence of free radical formation. J Neurochem. 1988;51:1960-3.
11. Trotti D, Danbolt NC, Volterra A. Glutamate transporters are oxidantvulnerable: a molecular link between oxidative and excitotoxic. neurodegeneration. Trends Pharmacol Sci. 1998;19:328-34.
12. Santamaría A, Salvatierra-Sánchez R, Vázquez-Román B, et al. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J Neurochem. 2003;86:479-88.
13. Santamaría A, Jiménez-Capdeville ME, Camacho A, Rodríguez-Martínez E, Flores A, Galván-Arzate S. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport. 2001;12: 2693-6.
14. Behan WM, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol. 1999;128:1754-60.
15. Rodríguez-Martínez E, Camacho A, Maldonado PD, et al. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res. 2000;858:436-9.
16. Pérez-De La Cruz V, González-Cortés C, Galván-Arzate S, et al. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrinate iron (III). Neuroscience. 2005;135:463-74.
17. Silva-Adaya D, Pérez-De La Cruz V, Herrera-Mundo MN, et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine. J Neurochem. 2008;105:677-89.
18. Ryu JK, Choi HB, McLarnon JG. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience. 2006;141:1835-48.
19. Ganzella M, Jardim FM, Boeck CR, Vendite D. Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice. Neurosci Res. 2006;55:397-402.
20. Jacquard C, Trioulier Y, Cosker F, et al. Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. FASEB J. 2006;20:1021-3.
21. Pérez-De La Cruz V, Elinos-Calderón D, Carrillo-Mora P, et al. Time-course correlation of early toxic events in three models of striatal damage: modulation by proteases inhibition. Neurochem Int. 2010;56:834-42.
22. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation. 2005;2:16.
23. Guillemin GJ, Cullen KM, Lim CK, et al. Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007;27:12884-92.
24. Owe-Young R, Webster NL, Mukhtar M, et al. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J Neurochem. 2008;105:1346-57.
25. Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, Guillemin GJ. Effects of kynurenine pathway metabolites on intracellular NAD+ synthesis and cell death in human primary astrocytes and neurons. Int J Tryptophan Res. 2009;2:63-71.
26. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77-86.
27. Poeggeler B, Rassoulpour A, Wu HQ, Guidetti P, Roberts RC, Schwarcz R. Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity. Neuroscience. 2007;148:188-97.
28. Tasset I, Pérez-De La Cruz V, Elinos-Calderón D, et al. Protective effect of tert-butylhydroquinone on the quinolinic acid-induced toxicity in rat striatal slices: role of the Nrf2-antioxidant response element pathway. Neurosignals. 2010;18:24-31.
29. Cuevas E, Lantz S, Newport G, et al. On the early toxic effect of quinolinic acid: involvement of RAGE. Neurosci Lett. 2010;474:74-8.
30. Maldonado PD, Molina-Jijón E, Villeda-Hernández J, Galván-Arzate S, Santamaría A, Pedraza-Chaverrí J. NAD(P)H oxidase contributes to neurotoxicityin an excitotoxic/prooxidant model of Huntington's disease in rats: protective role of apocynin. J Neurosci Res. 2010;88:620-9.
31. Kalonia H, Kumar P, Kumar A, Nehru B. Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-a levels alterations in rats. Neuroscience. 2010;171:284-99.
32. Kalonia H, Kumar P, Kumar A. Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats. Behav Brain Res. 2010;216:220-8.
33. Velloso NA, Dalmolin GD, Fonini G, et al. Spermine attenuates behavioral and biochemical alterations induced by quinolinic acid in the striatum of rats. Brain Res. 2008;1198:107-14.
34. Mallozzi C, Martire A, Domenici MR, Metere A, Popoli P, Di Stasi AM. L-NAME reverses quinolinic acid-induced toxicity in rat corticostriatal slices: Involvement of src family kinases. J Neurosci Res. 2007;85:2770-7.
35. Santamaría A, Vázquez-Román B, La Cruz VP, et al. Selenium reduces the proapoptotic signaling associated to NF-kappaB pathway and stimulates glutathione peroxidase activity during excitotoxic damage produced by quinolinate in rat corpus striatum. Synapse. 2005;58:258-66.
36. Vega-Naredo I, Poeggeler B, Sierra-Sánchez V, et al. Melatonin neutralizes neurotoxicity induced by quinolinic acid in brain tissue culture. J Pineal Res. 2005;39:266-75.
37. Maharaj DS, Maharaj H, Antunes EM, et al. 6-Hydroxymelatonin protects against quinolinic acid-induced oxidative neurotoxicity in the rat hippocampus. J Pharm Pharmacol. 2005;57:877-81.
38. Elinos-Calderón D, Robledo-Arratia Y, Pérez-De La Cruz V, et al. Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine. J Neural Transm. 2010;117:35-44.
39. Müller N, Myint AM, Schwarz MJ. The impact of neuroimmune dysregulation on neurprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin Neurosci. 2009;11:319-32.
40. Graham RK, Pouladi MA, Joshi P, et al. Differential susceptibility to excitotoxic stress in YAC128 mouse model of Huntington disease between initiation and progression of disease. J Neurosci. 2009;29:2193-204.